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Motexafin lutetium (MLu), an expanded porphyrin, decreases Mats in rabbit atheroma when locally administered and photoactivated. We studied the effect of MLu phototherapy on human Mats in vitroand the effect of systemic MLu followed by local photoactivation (732nm) on vascular Mac burden, as well as thermal effects of balloon Illumination in viva Methods: In vitro Human monocyies (THP-1) were cultured with MLu (10 pg/ml), then photoactivated (2 J/cm?; drug uptake (histofluorescence), growth and differentiation (cell count) were assessed. In viva: After 14 wks on 2% chol, 48 rabbits were randomized to 7 groups: (1) Control (5% mannitol); (2) MLu (10 mg/kg); (3) Light (100 J/cm' in balloon, 300 J/cm' with bare fiber); and MLu + light, 10, 30. 100 and 300 J/cm' as groups 4-7. Light was delivered to upper thoracic aolta via a balloon and lower thorawl abdominal aorta by a bare fiber for 900 secslsite, 24h after i.v. MLu. AHer 3 more wks, aortas were examined for plaque (I/M ratios) and Mats (RAM-1 1 stain of in-stent restenosis as well as neointimal hyperplasia is only one of the major responsible mechanisms of restenosis aHer angioplasty. The purpose of this study was to assess the long-term effects of octreotide on the in-stent restenosis at six-month follow-up coronary angiography. Methods: In a placebo-controlled, randomized study, of the 176 patients, the finally evaluable 148 patients with significant coronary disease (stenosis > 70%) amenable to stenting were randomly allocated to octreotide therapy with a dose of 300 mg or placebo subcutaneously every eight hours for three weeks. The primary endpoint of the study was the restenosis rate after stenting at 6-month follow-up. Restenosis was defined as recurrent lumen diameter stenosis >50% at follow-up angiography. Stenting was considered successful if the residual diameter stenosis was less than 10%.
Results: There was no sianiflcant difference between octreotide and placebo aroups in _.
the pre (85.8% * %6.5 and 85% * %9.4, paO.05) and poststenting mean percent diameter stenoses (7.6% * 2.1% vs. 7.4% * 2.2%. 0~0.05) resoectivelv. The mean oercent I , diameter stenoses at the B-month control angiographies of octreotide and placebo groups were significantly different from each other. (35% * 19.2% vs. 18.8% * 14.2 respectively, p=O.OOl). At the six-month, the restenosis rate was 12% (9 of 76 patients) in the octreotide group and 26% (19 of 72 patients) in the control group. The difference between the two groups was significant (pcO.05). We found an OR of 0.37 with a 95% Cl of 0.14-0.96 (p=O.O36), when octreotide was given to our patients undergoing to stenting.
Conclusion: Due to our findings, octreotide caused a significant reduction on in-stent restenosis. We proposed that these results could be related to the inhibiting effect of octreotide on neointimal hyperplasia after stenting. Previous studies have reported treatment with the HMG-CoA reductase inhibitor simvastatin reduces serum C-reactive protein (CRP) levels, suggesting an antiinflammatory effect that appears to be fully established within 4 weeks of commencing therapy. Coronary angloplasty is associated with an acute increase rn serum inflammatory markers which may predict early complications.
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The effect of simvastatin on this inflammatory marker rise is unknown. The aim of this study was to determine whether pre-treatment with slmvastatin reduces the inflammatory response to coronary angioplasty.
Methods:
We studied 92 patients (mean age 60*10 years) randomised to simvastatin 40mgld (n=52) or placebo (n=40) a median of 1.9 months (IQR 0.9 to 3.6 months) before elective coronary angioplasty. All patients were taking aspirin 150mgIday unless there was a specific contraindication (aspirin use 92% for simvastatin group, 95% for placebo group, p=ns). CRP was measured by high sensitivity immunoassay on serum samples taken immediately prior to and 48 hours after angioplasty.
Results:
The CRP (median[lQR]) immediately prior to angioplasty was 1.3mgIl (0.71-2.43) for the placebo group, versus 1.46mgA (0.67-2.14) for the simvastatin group, p=O.79. CRP increased post-PC1 for both groups (p<O.OOi for both simvastatin and placebo). Simvastatin did not alter this inflammatory response; the increase in CRP (preangioplasty to 48 hours post-angioplasty) for patients randomised to simvastatin was 4.68mgIl (IQR 2.9 to 10.3) compared to 5.1fJmg/l (IQR 2.2-9.3) for placebo, (p=O.96).
Exclusion of patients on simvastatin for less than 4 weeks prior to angioplasty did not alter this result.
Conclusion:
There is an increase in CRP measured 48 hours after angioplasty, confirming an inflammatory response. Simvastatin did not significantly influence this inflammatory response.
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Neither Periprocedural Pregnancy-Associated Plasma Protein A nor C-Reactive Protein Levels Predict Restenosis to 72 hours, but the effect of this inflammatory response on restenosis IS unclear. The aim of this study was to determine whether peri-procedural levels of PAPP-A and/or CRP predict restenosis.
Methods:
We studied 136 patients with stable angina who underwent elective PCI with stored peri-procedural blood samples and corresponding pre-. post-, and six month coronary angiograms; age (mean&D) 59+10 yrs, 83% male. slant insertion rate 14%. CRP and PAPP-A were measured by high sensitivity immunoassay on EDTA-plasma samples which had been taken immediately prior to, and 48 hours post, PCI. All results are expressed as median (IQR). Restenosis (diameter stenosis ~50%) six months after PCI was determined by quantitative coronary angiographic @CA) analysis. In multi vessel PCI (39% of patients), analysis was done on a "per patient" basis by averaging the percent diameter stenosis of all lesions.
Results:
PCI was associated with a significant rise in both CRP and PAPP-A levels; CRP prior to PCI 1.2mgA (0.7-2.2), post-PC1 6.6mg/l (4.0.13.2), pcO.0001, PAPP-A prior to PCI 4.lmlUll (3.3&l), post-PC1 b.BmlU/I (4.3-7.2), p<O.OOOl. The median stenosis at six months was 46% (IQR 34.63%) and the binary restenosis rate was 42%. There were
